Identification of a novel SEPT9-ABL1 fusion gene in a patient with T-cell prolymphocytic leukemia

Leukemia Research Reports

Volumn 3, Issue 2, 2014, Pages 54-57

  Suzuki, Rikio ^a,b   Matsushita, Hiromochi ^a   Kawai, Hidetsugu ^a   Matsuzawa, Hideyuki ^a   Tsuboi, Kosuke ^a   Watanabe, Shigeki ^b   Kawada, Hiroshi ^a   Ogawa, Yoshiaki ^a   Ando, Kiyoshi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Ebina General Hospital   (Japan)

Author keywords

SEPT9 ABL1; T cell prolymphocytic leukemia; Tyrosine kinase inhibitors

Indexed keywords

ASPARAGINASE; CD2 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; HYDROXYUREA; IMATINIB; LACTATE DEHYDROGENASE; METHOTREXATE; NELARABINE; PREDNISOLONE; VINCRISTINE;

ABL1 GENE; AGED; ARTICLE; AUTOPSY; BIOCHEMISTRY; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CHROMOSOME ANALYSIS; DRUG MEGADOSE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENERALIZED LYMPHADENOPATHY; HEPATOMEGALY; HUMAN; HUMAN TISSUE; KIDNEY HYPERTROPHY; LABORATORY TEST; LEUKEMIC INFILTRATION; LEUKOCYTOSIS; LUNG DISEASE; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE; POLYMERASE CHAIN REACTION; PROLYMPHOCYTIC LEUKEMIA; SEPT9 GENE; SPLENOMEGALY; T CELL LEUKEMIA; T CELL PROLYMPHOCYTIC LEUKEMIA; THERAPY RESISTANCE; WESTERN BLOTTING;

EID: 84907564413     PISSN: 22130489     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lrr.2014.06.004     Document Type: Article

References (11)

1. Matutes E., Brito-Babapulle V., Swansbury J., Ellis J., Morilla R., Dearden C., et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991, 78(12):3269-3274.
2. Hoyer J.D., Ross C.W., Li C.Y., Witzig T.E., Gascoyne R.D., Dewald G.W., et al. True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood 1995, 86(3):1163-1169.
3. Dearden C.E. T-cell prolymphocytic leukemia. Med Oncol 2006, 23(1):17-22.
4. Greuber E.K., Smith-Pearson P., Wang J., Pendergast A.M. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 2013, 13(8):559-571.
5. De Braekeleer E., Douet-Guilbert N., Rowe D., Bown N., Morel F., Berthou C., et al. ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol 2011, 86(5):361-371.
6. Mostowy S., Cossart P. Septins: the fourth component of the cytoskeleton. Nat Rev Mol Cell Biol 2012, 13(3):183-194.
7. Connolly D., Abdesselam I., Verdier-Pinard P., Montagna C. Septin roles in tumorigenesis. Biol Chem 2011, 392(8-9):725-738.
8. Cerveira N., Bizarro S., Teixeira M.R. MLL-SEPTIN gene fusions in hematological malignancies. Biol Chem 2011, 392(8-9):713-724.
9. Boggon T.J., Eck M.J. Structure and regulation of Src family kinases. Oncogene 2004, 23(48):7918-7927.
10. Masuzawa A., Kiyotani C., Osumi T., Shioda Y., Iijima K., Tomita O., et al. Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript. Eur J Haematol 2014, 92(3):263-267.
11. Tomita O., Iijima K., Ishibashi T., Osumi T., Kobayashi K., Okita H., et al. Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1. Leuk Res 2014, 38(3):361-370.